Clinical product manufacturer Trinity Biotech has acquired US-based company Bartel in a deal worth $9.3m.
Bartel is a division of Intracel Corporation based in Washington State, and manufactures detection kits for herpes and flu.
The $9.3m purchase price comprises $3.2m in shares, and the $6.1m balance in cash.
Trinity's CEO Ronan O'Caoimh says the two companies' product lines are complementary, and that the Bartel sales force will improve Trinity's penetration into the US market.
